All Updates

All Updates

icon
Filter
M&A
AbbVie acquires Celsius Therapeutics for USD 250 million to advance anti-inflammation drug development
Precision Medicine
Jun 27, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 27, 2024

AbbVie acquires Celsius Therapeutics for USD 250 million to advance anti-inflammation drug development

M&A

  • AbbVie has announced the completion of the acquisition of Celsius Therapeutics. As per the agreement, AbbVie has acquired all outstanding shares of Celsius for USD 250 million, subject to certain customary adjustments.

  • Post acquisition, AbbVie plans to further advance the development of Celsius’ CEL383, , a potential first-in-class anti-TREM1 antibody that has completed a Phase I clinical trial for inflammatory bowel disease (IBD). The company states that the acquisition of Celsius and its potential drug, CEL383, is a promising step toward a new approach in IBD treatment.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.